Vivet Therapeutics has raised a huge €37.5M in Series A to help bring a new gene therapy technology for rare liver diseases to the clinic.
Vivet Therapeutics has managed to attract some of the hottest biotech investors in Europe in its Series A. Led by Novartis Venture Fund and Columbus Venture Partners, and also counting with Roche Venture Fund, HealthCap, Kurma Partners and Ysios Capital, the round has injected a massive €37.5M in the early-stage biotech.
vivet therapeutics gene therapyFounded in 2016, Vivet develops gene therapies based on technology in-licensed from the non-profit Fundación para la Investigación Médica Aplicada (FIMA), associated with the University of Navarra, Spain. The technology is based on a next-generation adeno-associated virus (AAV) optimized for increased gene expression in the liver while reducing immunogenic responses.
Vivet Therapeutic’s lead program, VTX801, targets Wilson Disease, a rare disorder that only affects around 15,000 people in Europe. It is caused by a defective gene encoding the ATP7B protein implicated in copper metabolism in the liver. Patients suffering from Wilson Disease accumulate copper, which causes severe damage to the liver and the brain. Current treatments are not effective in 45% of patients and do not completely eliminate neurological symptoms.
